Topical @entity927 as an adjuvant treatment in XXXX : Side-by-side comparison clinical study.

@entity1 @entity24451 @entity894 @entity1709 @entity927 @entity272
BACKGROUND: @entity927 ( @entity24451 ) is a novel therapeutic agent for hyperpigmented @entity272 . The efficacy and safety of topical @entity24451 in @entity1 with @entity1709 has not been heretofore studied. The main objective of this study is to evaluate the efficacy and safety of topical @entity24451 combined with intense pulsed light (IPL) treatment in Asians with @entity1709 . METHODS: A randomized, split-face (internally controlled) study was conducted in 15 @entity1 who received four monthly sessions of IPL to both sides of the face. Topical @entity24451 or vehicle was applied to a randomly assigned side during and after IPL treatment. @entity1 were followed up for 12 weeks after completing the IPL treatments. Baseline and follow-up @entity894 ( @entity894 ; measured by Mexameter  , Courage and Khazaka, Cologne, Germany) and modified @entity1709 area and severity index (mMASI) scores were determined. RESULTS: Thirteen subjects completed the study without serious adverse events. @entity894 and mMASI decreased significantly from baseline to 12 weeks after the last IPL treatment on the topical @entity24451 side but not on the vehicle side. The efficacy of topical @entity24451 in preventing rebound pigmentation after IPL treatment was also statistically significant. CONCLUSION: Topical @entity24451 can be considered an effective and safe adjuvant to conventional treatment for @entity1709 .
